Guanhao Biotech Co Ltd
Guanhao Biotech Co.,Ltd. develops, manufactures, and sells regenerative medicines and life sciences products primarily in China. It offers NormalGEN, a dura repair patch; GrandNeuro, a dura repair patch; ThormalGEN, a surgical patch; DermalGEN, a wound dressing product; IREAL breast patch; and Youvision corneal graft, as well as license in intraocular lenses. The company also provides Biological … Read more
Guanhao Biotech Co Ltd (300238) - Total Assets
Latest total assets as of September 2025: CN¥774.51 Million CNY
Based on the latest financial reports, Guanhao Biotech Co Ltd (300238) holds total assets worth CN¥774.51 Million CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Guanhao Biotech Co Ltd - Total Assets Trend (2007–2024)
This chart illustrates how Guanhao Biotech Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Guanhao Biotech Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Guanhao Biotech Co Ltd's total assets of CN¥774.51 Million consist of 35.2% current assets and 64.8% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 14.2% |
| Accounts Receivable | CN¥61.75 Million | 8.2% |
| Inventory | CN¥78.46 Million | 10.4% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥99.32 Million | 13.2% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2007–2024)
This chart illustrates how Guanhao Biotech Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Guanhao Biotech Co Ltd's current assets represent 35.2% of total assets in 2024, a decrease from 73.0% in 2007.
- Cash Position: Cash and equivalents constituted 14.2% of total assets in 2024, down from 52.1% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 13.0% of total assets, an increase from 11.0% in 2007.
- Asset Diversification: The largest asset category is intangible assets at 13.2% of total assets.
Guanhao Biotech Co Ltd Competitors by Total Assets
Key competitors of Guanhao Biotech Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Guanhao Biotech Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Guanhao Biotech Co Ltd generates 0.50x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Guanhao Biotech Co Ltd generates $ 3.63 in net profit.
Guanhao Biotech Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.97 | 1.67 | 1.45 |
| Quick Ratio | 1.43 | 1.21 | 1.03 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥148.43 Million | CN¥ 109.33 Million | CN¥ 135.33 Million |
Guanhao Biotech Co Ltd - Advanced Valuation Insights
This section examines the relationship between Guanhao Biotech Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.26 |
| Latest Market Cap to Assets Ratio | 0.58 |
| Asset Growth Rate (YoY) | 11.2% |
| Total Assets | CN¥754.40 Million |
| Market Capitalization | $440.30 Million USD |
Valuation Analysis
Below Book Valuation: The market values Guanhao Biotech Co Ltd's assets below their book value (0.58 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Guanhao Biotech Co Ltd's assets grew by 11.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Guanhao Biotech Co Ltd (2007–2024)
The table below shows the annual total assets of Guanhao Biotech Co Ltd from 2007 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥754.40 Million | +11.17% |
| 2023-12-31 | CN¥678.59 Million | +1.25% |
| 2022-12-31 | CN¥670.21 Million | -39.00% |
| 2021-12-31 | CN¥1.10 Billion | -3.17% |
| 2020-12-31 | CN¥1.13 Billion | -1.27% |
| 2019-12-31 | CN¥1.15 Billion | -29.88% |
| 2018-12-31 | CN¥1.64 Billion | -4.60% |
| 2017-12-31 | CN¥1.72 Billion | +1.77% |
| 2016-12-31 | CN¥1.69 Billion | +109.20% |
| 2015-12-31 | CN¥807.02 Million | +30.26% |
| 2014-12-31 | CN¥619.54 Million | +8.21% |
| 2013-12-31 | CN¥572.52 Million | +5.63% |
| 2012-12-31 | CN¥541.99 Million | +9.26% |
| 2011-12-31 | CN¥496.06 Million | +110.18% |
| 2010-12-31 | CN¥236.02 Million | +92.99% |
| 2009-12-31 | CN¥122.30 Million | +97.83% |
| 2008-12-31 | CN¥61.82 Million | +51.89% |
| 2007-12-31 | CN¥40.70 Million | -- |